Protein C inhibitor, a serpin with functions in- and outside vascular biology

Summary

Human protein C inhibitor (PCI), a serpin-type protease inhibitor originally described as an inhibitor of activated protein C, has broad protease reactivity. In addition to its activities within the blood clotting and fibrinolytic cascades, it seems to participate in several biological processes including reproductiorn and tumor growth. This review summarizes the current understanding of PCI function, regulation, and potential biological role.

Keywords

Serpins - phospholipids - proteases

• References

• 1 Silverman GA, Bird PI, Carrell RW. et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-33296.
• 2 Grigoryev SA, Bednar J, Woodcock CL. MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member. J Biol Chem 1999; 274: 5626-5636.
• 3 De Gregorio E, Han SJ, Lee WJ. et al. An immuneresponsive serpin regulates the melanization cascade in Drosophila. Dev Cell 2002; 3: 581-592.
• 4 Hejgaard J. Inhibitory plant serpins with a sequence of three glutamine residues in the reactive center. Biol Chem 2005; 386: 1319-1323.
• 5 Komiyama T, Quan LT, Salvesen GS. Inhibition of cystein and serine proteinases by the cowpox virus serpin CRMA. Adv Exp Med Biol 1996; 389: 173-176.
• 6 Suzuki K, Deyashiki Y, Nishioka J. et al. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 1987; 262: 611-616.
• 7 Quinsey NS, Greedy AL, Bottomley SP. et al. Antithrombin: in control of coagulation. Int J Biochem Cell Biol 2004; 36: 386-389.
• 8 Tollefsen DM. Heparin cofactor II. Adv Exp Med Biol 1997; 425: 35-44.
• 9 Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
• 10 Ny T, Mikus P. Plasminogen activator inhibitor type-2. A spontaneously polymerizing serpin that exists in two topological forms. Adv Exp Med Biol 1997; 425: 123-130.
• 11 Coughlin PB. Antiplasmin: the forgotten serpin?. FEBS J 2005; 272: 4852-4857.
• 12 Miao RQ, Agata J, Chao L. et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100: 3245-3252.
• 13 Geiger M, Zechmeister-Machhart M, Uhrin P. et al. Protein C inhibitor (PCI). Immunopharmacology 1996; 32: 53-56.
• 14 Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236.
• 15 Tanaka T, Ohkubo H, Nakanishi S. Common structural organization of the angiotensinogen and the alpha 1-antitrypsin genes. J Biol Chem 1984; 259: 8063-8065.
• 16 Edgar P, Stein P. Hormone binding site of corticosteroid binding globulin. Nat Struct Biol 1995; 2: 196-197.
• 17 Flink IL, Bailey TJ, Gustafson TA. et al. Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: close homology to the serine antiproteinases. Proc Natl Acad Sci USA 1986; 83: 7708-7712.
• 18 Sager R, Sheng S, Pemberton P. et al. Maspin. A tumor suppressing serpin. Adv Exp Med Biol 1997; 425: 77-88.
• 19 Koide T, Asada S, Nagata K. Substrate recognition of collagen-specific molecular chaperone HSP47. Structural requirements and binding regulation. J Biol Chem 1999; 274: 34523-34526.
• 20 Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980; 66: 1186-1189.
• 21 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168.
• 22 Espana F, Berrettini M, Griffin JH. Purification and characterization of plasma protein C inhibitor. Thromb Res 1989; 55: 369-384.
• 23 Meijers JCM, Kanters DHAJ, Vlooswijk RAA. et al. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237.
• 24 Geiger M, Huber K, Wojta J. et al. Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo. Blood 1989; 74: 722-728.
• 25 Ecke S, Geiger M, Resch I. et al. Inhibition of tissue kallikrein by protein-C inhibitor – Evidence for identity of protein-C inhibitor with the kallikrein bindingprotein. J Biol Chem 1992; 267: 7048-7052.
• 26 Luo LY, Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol Chem 2006; 387: 813-816.
• 27 Hermans JM, Jones R, Stone SR. Rapid inhibition of the sperm protease acrosin by protein C inhibitor. Biochemistry 1994; 33: 5440-5444.
• 28 Zheng XL, Geiger M, Ecke S. et al. Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa. Am J Physiol 1994; (Cell Physiol 36) C466-C472.
• 29 Suzuki K, Nishioka J, Kusumoto H. et al. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem (Tokyo) 1984; 95: 187-195.
• 30 Rezaie AR, Cooper ST, Church FC. et al. Protein C inhibitor is a potent inhibitor of the thrombinthrombomodulin complex. J Biol Chem 1995; 270: 25336-25339.
• 31 Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32 (Suppl. 01) 49-60.
• 32 Szabo R, Netzel-Arnett S, Hobson JP. et al. Matriptase- 3 is a novel phylogenetically preserved membrane- anchored serine protease with broad serpin reactivity. Biochem J 2005; 390: 231-242.
• 33 Hobson JP, Netzel-Arnett S, Szabo R. et al. Mouse DESC1 is located within a cluster of seven DESC-1 like gened and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem 2004; 279: 46981-46994.
• 34 Elisen MG, Maseland MH, Church FC. et al. Role of the A+ helix in heparin binding to protein C inhibitor. Thromb Haemost 1996; 75: 760-766.
• 35 Geiger M, Priglinger U, Griffin JH. et al. Urinary protein C inhibitor. Glycosaminoclycans synthesized by the epithelial kidney cell line TCL-598 enhance its interaction with urokinase. J Biol Chem 1991; 266: 11851-11857.
• 36 Kuhn LA, Griffin JH, Fisher CL. et al. Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci USA 1990; 87: 8506-8510.
• 37 Pratt CW, Church FC. Heparin binding to protein C inhibitor. J Biol Chem 1992; 267: 8789-8794.
• 38 Prendes MJ, Bielek E, Zechmeister-Machhart M. et al. Synthesis and ultrastructural localization of protein C inhibitor in human platelets and megakaryocytes. Blood 1999; 94: 1300-1312.
• 39 Ecke S, Geiger M, Binder BR. Glycosaminoglycans regulate the enzyme specificity of protein-C inhibitor. Ann NY Acad Sci 1992; 667: 84-86.
• 40 Nishioka J, Ning M, Hayashi T. et al. Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles. J Biol Chem 1998; 273: 11281-11287.
• 41 Laurell M, Christensson A, Abrahamsson PA. et al. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 1992; 89: 1094-1101.
• 42 Espana F, Gilabert J, Estelles A. et al. Functionally active protein C inhibitor/plasminogen activator inhibitor- 3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991; 64: 309-320.
• 43 Hayashi T, Nishioka H, Kamada H. et al. Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions. J Thromb Haemost 2004; 2: 949-961.
• 44 Uhrin P, Dewerchin M, Hilpert M. et al. Disruption of the protein C inhibitor gene results in impaired spermatogenesis and male infertility. J Clin Invest 2000; 106: 1531-1539.
• 45 Radtke KP, Fernandez JA, Greengard JS. et al. Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest 1994; 94: 2117-2124.
• 46 Krebs M, Uhrin P, Vales A. et al. Protein C inhibitor is expressed in keratinocytes of human skin. J Invest Dermatol 1999; 113: 32-37.
• 47 Geiger M, Huber K, Wojta J. et al. Complexformation between urokinase and plasma protein-C inhibitor in vitro and in vivo. Blood 1989; 74: 722-728.
• 48 Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45-53.
• 49 Laurell M, Stenflo J, Carlson TH. Turnover of *I-protein C inhibitor and *I-alpha 1-antitrypsin and their complexes with activated protein C. Blood 1990; 76: 2290-2295.
• 50 Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost 2003; 1: 1663-1670.
• 51 Jerabek I, Zechmeister-Machhart M, Binder BR. et al. Binding of retinoic acid by the inhibitory serpin protein C inhibitor. Eur J Biochem 2001; 268: 5989-5996.
• 52 Wagenaar GT, van Vuuren AJ, Girma M. et al. Characterization of transgenic mice that secrete functional human protein C inhibitor into the circulation. Thromb Haemost 2000; 83: 93-101.
• 53 Zechmeister-Machhart M, Hufnagl P, Uhrin P. et al. Molecular cloning and sequence analysis of the mouse protein C inhibitor gene. Gene 1997; 186: 61-66.
• 54 Meijers JCM, Chung DW. Organization of the gene coding for human protein C inhibitor (plasminogen activator inhibitor-3). Assignment of the gene to chromosome 14. J Biol Chem 1991; 266: 15028-15034.
• 55 Hayashi T, Suzuki K. Gene organization of human protein C inhibitor, a member of SERPIN family proteins encoded in five exons. Int J Hematol 1993; 58: 213-224.
• 56 Carroll VA, Griffiths MR, Geiger M. et al. Plasma protein C inhibitor is elevated in survivors of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 114-118.
• 57 Meijers JC, Marquart JA, Bertina RM. et al. Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis. Brit J Hematol 2002; 118 2002: 604-609.
• 58 Sayinalp N, Haznedaroglu IC, Buyukasik Y. et al. Protein C inhibitor and serum amyloid A in immune thrombocytopaenic purpura. J Int Med Res 2004; 32: 62-65.
• 59 Kölbel T, Strandberg K, Mattiasson I. et al. Activated protein C-protein C inhibitor complex: A new biological marker for aortic aneurisms. J VAsc Surg 2006; 43: 935-939.
• 60 He S, Lin YL, Liu YX. Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility. Mol Hum Reprod 1999; 5: 513-519.
• 61 Zheng X, Zechmeister-Machhart M, Uhrin P. et al. Effect of protein C inhibitor (PCI) on in vitro fertilization. Immunopharmacology 1996; 33: 140-142.
• 62 Elisen MG, van Kooij RJ, Nolte MA. et al. Protein C inhibitor may modulate human sperm-oocyte interactions. Biol Reprod 1998; 58: 670-677.
• 63 Moore A, Penfold LM, Johnson JL. et al. Human sperm-egg binding is inhibited by peptides corresponding to core region of an acrosomal serine protease inhibitor. Mol Reprod Dev 1993; 34: 280-291.
• 64 Dano K, Behrendt N, Hoyer-Hansen G. et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-681.
• 65 Skrzydlewska E, Sulkowska M, Koda M. et al. Proteolytic- antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005; 11: 1251-1266.
• 66 Sieben NL, Oosting J, Flanagan AM. et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005; 23: 7257-7264.
• 67 Michael IP, Sotiropoulou G, Pampalakis G. et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005; 280: 14628-14635.
• 68 Wakita T, Hayashi T, Nishioka J. et al. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreases in renal cell carcinoma. Int J Cancer 2004; 108: 516-523.
• 69 Cao Y, Becker C, Lundwall A. et al. Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate 2003; 57: 196-204.
• 70 Glasscock LN, Rehault SM, Gregory CW. et al. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. Exp Mol Pathol 2005; 79: 23-32.